Mihir Wechalekar, Fracp

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/798759/publications.pdf

Version: 2024-02-01

331259 1,576 59 21 citations h-index papers

g-index 63 63 63 2747 docs citations times ranked citing authors all docs

315357

38

#	Article	IF	CITATIONS
1	Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Annals of the Rheumatic Diseases, 2014, 73, 328-335.	0.5	222
2	Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Research and Therapy, 2013, 15, R136.	1.6	212
3	Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use. Annals of the Rheumatic Diseases, 2015, 74, 89-95.	0.5	129
4	Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus. Arthritis Research and Therapy, 2018, 20, 85.	1.6	83
5	Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression. PLoS ONE, 2018, 13, e0192704.	1.1	82
6	Colchicine for acute gout. The Cochrane Library, 2014, , CD006190.	1.5	77
7	CD40L-Dependent Pathway Is Active at Various Stages of Rheumatoid Arthritis Disease Progression. Journal of Immunology, 2017, 198, 4490-4501.	0.4	73
8	Active foot synovitis in patients with rheumatoid arthritis: Applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement. Arthritis and Rheumatism, 2012, 64, 1316-1322.	6.7	45
9	Australian and New Zealand recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion in the 3e Initiative. International Journal of Rheumatic Diseases, 2015, 18, 341-351.	0.9	43
10	The novel cytokine Metrnl/IL-41 is elevated in Psoriatic Arthritis synovium and inducible from both entheseal and synovial fibroblasts. Clinical Immunology, 2019, 208, 108253.	1.4	43
11	Non-steroidal anti-inflammatory drugs for acute gout. The Cochrane Library, 2014, , CD010120.	1.5	40
12	Triple DMARD treatment in early rheumatoid arthritis modulates synovial T cell activation and plasmablast/plasma cell differentiation pathways. PLoS ONE, 2017, 12, e0183928.	1.1	33
13	A Multicenter Retrospective Analysis Evaluating Performance of Synovial Biopsy Techniques in Patients With Inflammatory Arthritis. Arthritis and Rheumatology, 2018, 70, 702-710.	2.9	32
14	Active Foot Synovitis in Patients With Rheumatoid Arthritis: Unstable Remission Status, Radiographic Progression, and Worse Functional Outcomes in Patients With Foot Synovitis in Apparent Remission. Arthritis Care and Research, 2016, 68, 1616-1623.	1.5	31
15	Utility of arthroscopic guided synovial biopsy in understanding synovial tissue pathology in health and disease states. World Journal of Orthopedics, 2014, 5, 566.	0.8	30
16	The Efficacy and Safety of Treatments for Acute Gout: Results from a Series of Systematic Literature Reviews Including Cochrane Reviews on Intraarticular Glucocorticoids, Colchicine, Nonsteroidal Antiinflammatory Drugs, and Interleukin-1 Inhibitors. Journal of rheumatology Supplement, The, 2014, 92, 15-25.	2.2	29
17	Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups. Arthritis Research and Therapy, 2018, 20, 265.	1.6	29
18	Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years. Arthritis Research and Therapy, 2015, 17, 48.	1.6	24

#	Article	IF	CITATIONS
19	Interleukin-1 inhibitors for acute gout. The Cochrane Library, 2014, 2014, CD009993.	1.5	23
20	Treatment of Asymptomatic Hyperuricemia for the Prevention of Gouty Arthritis, Renal Disease, and Cardiovascular Events: A Systematic Literature Review. Journal of rheumatology Supplement, The, 2014, 92, 70-74.	2.2	23
21	Adherence to combination DMARD therapy and treatment outcomes in rheumatoid arthritis: a longitudinal study of new and existing DMARD users. Rheumatology International, 2017, 37, 897-904.	1.5	23
22	Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy., 2020, 8, e000281.		23
23	Prolonged Remission of Chronic Reactive Arthritis Treated With Three Infusions of Infliximab. Journal of Clinical Rheumatology, 2010, 16, 79-80.	0.5	19
24	Factors associated with medication adherence in a longitudinal study of rheumatoid arthritis patients. International Journal of Clinical Practice, 2019, 73, e13375.	0.8	17
25	Intra-articular glucocorticoids for acute gout. The Cochrane Library, 2013, , CD009920.	1.5	16
26	Synovial biopsies in inflammatory arthritis: precision medicine in rheumatoid arthritis. Expert Review of Molecular Diagnostics, 2020, 20, 315-325.	1.5	16
27	Nonsteroidal Anti-inflammatory Drugs for Treatment of Acute Gout. JAMA - Journal of the American Medical Association, 2015, 313, 2276.	3 . 8	12
28	Disease activity trajectories in early rheumatoid arthritis following intensive <scp>DMARD</scp> therapy over 3 years: association with persistence to therapy. International Journal of Rheumatic Diseases, 2017, 20, 1447-1456.	0.9	12
29	Colchicine for acute gout. The Cochrane Library, 2021, 2021, CD006190.	1.5	12
30	Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort. Journal of Rheumatology, 2016, 43, 1643-1649.	1.0	11
31	Precision Medicine With Leflunomide: Consideration of the <i>DHODH</i> Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis. Arthritis Care and Research, 2021, 73, 983-989.	1.5	8
32	Achalasia cardia presenting as stridor. Respirology, 2008, 13, 1088-1090.	1.3	7
33	Osteoclast-Associated Receptor (OSCAR) Distribution in the Synovial Tissues of Patients with Active RA and TNF-α and RANKL Regulation of Expression by Osteoclasts In Vitro. Inflammation, 2017, 40, 1566-1575.	1.7	7
34	A Treat-to-Target Strategy Preserves Work Capacity in a Rheumatoid Arthritis Inception Cohort Treated With Combination Conventional DMARD Therapy. Journal of Clinical Rheumatology, 2017, 23, 131-137.	0.5	7
35	Determining the acceptable level of physician compliance with a treatâ€toâ€target strategy in early rheumatoid arthritis. International Journal of Rheumatic Diseases, 2017, 20, 576-583.	0.9	7
36	The 2018 OMERACT Synovial Tissue Biopsy Special Interest Group Report on Standardization of Synovial Biopsy Analysis. Journal of Rheumatology, 2019, 46, 1365-1368.	1.0	7

#	Article	IF	Citations
37	Non-steroidal anti-inflammatory drugs for acute gout. The Cochrane Library, 2021, 2021, CD010120.	1.5	7
38	Esophageal Adenocarcinoma and Hypertrophic Osteoarthropathy With Improvement Following Resection of Esophageal Cancer. Journal of Clinical Rheumatology, 2011, 17, 323-324.	0.5	6
39	Arthroscopic guided synovial biopsy in rheumatology: current perspectives. International Journal of Rheumatic Diseases, 2017, 20, 141-144.	0.9	6
40	Modifiable Lifestyle Factors Associated With Response to Treatment in Early Rheumatoid Arthritis. ACR Open Rheumatology, 2020, 2, 371-377.	0.9	6
41	Eosinophilic Vasculitis and Arteritic Anterior Ischemic Optic Neuropathy Associated With Anti-PD-L1 Therapy. Journal of Immunotherapy, 2022, 45, 51-55.	1.2	6
42	The synovium. , 2015, , 27-32.		5
43	An Extension of Pancreatic Pseudocysts in the Neck. Pancreas, 2007, 34, 171-173.	0.5	4
44	Proteomic mapping of rheumatoid factors in early rheumatoid arthritis. Arthritis and Rheumatology, 2020, 72, 2159-2161.	2.9	4
45	Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. Frontiers in Medicine, 2021, 8, 708168.	1.2	4
46	Neutrophils Require Activation to Express Functional Cell-Surface Complement Receptor Immunoglobulin. Frontiers in Immunology, 2022, 13, 840510.	2.2	4
47	THU0070â€RANKL, OPG and OSCAR but Not Dkk-1 Predict Radiographic Progression in An Inception Cohort of Seropositive Rheumatoid Arthritis (RA) Treated-To-Target with Combination Conventional DMARD Therapy. Annals of the Rheumatic Diseases, 2016, 75, 204.1-204.	0.5	3
48	Repeat serological testing for antiâ€citrullinated peptide antibody after commencement of therapy is not helpful in patients with seronegative rheumatoid arthritis. Internal Medicine Journal, 2020, 50, 818-822.	0.5	3
49	Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term?. International Journal of Clinical Practice, 2016, 70, 340-350.	0.8	2
50	PDâ€'1+ T cells contribute differently to the pathogenesis of rheumatoid arthritis and psoriatic arthritis. Polish Archives of Internal Medicine, 2017, 127, 813-814.	0.3	2
51	Multicentric myofibroblastic sarcoma. BMJ Case Reports, 2014, 2014, bcr2013201666-bcr2013201666.	0.2	1
52	Attenuation of the BTLA/HVEM Regulatory Network in the Circulation in Primary Sjögren's Syndrome. Journal of Clinical Medicine, 2022, 11, 535.	1.0	1
53	Interleukin-1 inhibitors for chronic gout. The Cochrane Library, 0, , .	1.5	O
54	THU0023â€Expression of OSCAR in The Synovium of Early RA Patients. Annals of the Rheumatic Diseases, 2016, 75, 185.2-185.	0.5	0

#	Article	IF	CITATIONS
55	THU0667â€A qualitative and quantitative comparison of synovial biopsy techniques during clinical trials of inflammatory arthritis. , 2017, , .		O
56	THU0011â€lmmune signal 2 checkpoint molecule expression in rheumatoid arthritis disease progression. , 2017, , .		0
57	FRI0016â€MUTATIONAL LANDSCAPE OF MYELODYSPLASTIC SYNDROME IN PATIENTS WITH AUTOIMMUNE RHEUMATOLOGICAL DISORDERS. , 2019, , .		O
58	Quantitative label-free characterisation and discrimination of osteoarthritis and rheumatoid arthritis based on hyperspectral autofluorescence features. , 2021, , .		0
59	The Mutation Profile of Myelodysplastic Syndrome Associated with Auto-Immune Rheumatological Disorders. Blood, 2018, 132, 3081-3081.	0.6	0